GLP-1 Agonists
Sort by:
Symposium on Diabetes and Cancer 2017: Novel Links and Treatments
Primer on Diabetes Management
FEATURING
Silvio Inzucchi
- 39,891 views
- June 16, 2017
- 195
ASPC 2019 Congress on CVD Prevention
Diabetes Treatment Guidelines Finally Have Entered the 21st Century - Almost
FEATURING
Ralph DeFronzo
- 11,582 views
- August 12, 2019
- 58
Cardiometabolic Health Congress (CMHC)
SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes
FEATURING
Lance Sloan
- 7,999 views
- June 17, 2019
- 48
Robert Busch
GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!
- 7,715 views
- August 14, 2023
- 112
McMaster University Department of Medicine
Semaglutide: Where Are We Now and Where Are We Going?
- 4,129 views
- September 27, 2023
- 23
Emory Diabetes Education Training Academy
Insulin Treatment in Patients with Type 2 Diabetes: When to Use Combination Therapy
FEATURING
Guillermo Umpierrez
- 3,780 views
- May 15, 2020
- 22
13th Orange County Symposium for Cardiovascular Disease Prevention
SGLT2 inhibitors and GLP-1 agonists: Why Are They Important and Which Do I Choose?
FEATURING
Yehuda Handelsman
- 3,406 views
- January 27, 2022
- 15
Diana Isaacs
Clinical Pearls & Updates on Incretins: The Diabetes Drugs Taking Hollywood by Storm
- 3,383 views
- August 29, 2023
- 19
UT Health San Antonio School of Medicine
Effective Treatment of T2DM Requires Combination Therapy
FEATURING
Ralph DeFronzo
- 2,505 views
- August 30, 2023
- 20
Susan Brian
Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist
- 2,149 views
- January 26, 2024
- 40
Cleveland Clinic | 12th Annual Obesity Summit
What To Do After Metformin: GLP-1, SGLT2 or DPP-4?
FEATURING
Kevin Pantalone
- 2,114 views
- December 3, 2017
- 5
Susan Brian
The Differences Between the Products of GLP1's and GLP/GIPs
- 2,104 views
- January 29, 2024
- 36
AHA 2023 Insights
AHA 2023 Insights: Reflections on SELECT Trial
FEATURING
Donna Ryan
- 2,070 views
- November 21, 2023
- 11
Inova Cherry Blossom Cardiovascular Symposium 2022
The Dangerous Intersection of Diabetes and Heart (and Kidney) Disease
FEATURING
Darren K. Mcguire
- 1,954 views
- August 2, 2022
- 13
Houston Methodist DeBakey Heart and Vascular Center
Should Cardiometabolic Protective Agents be the First Choice for Diabetic Patients?
FEATURING
Kershaw Patel
- 1,913 views
- November 15, 2022
- 8
Piedmont Heart Institute
Cardiometabolic Therapies: GLP-1 RAs and SGLT-2i
FEATURING
Jaime Burkle
- 1,738 views
- January 25, 2022
- 18
The Texas Heart Institute
The Role of GLP1 Receptor Agonists in Cardiovascular Care - Beyond Weight Loss
FEATURING
Joseph Rogers
- 1,599 views
- March 14, 2024
- 15